Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”-Reference-Cited by-同舟云学术

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

Published:2017-02-21 Issue:19 Volume:8 Page:31368-31385
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Feldmann Anja¹,Arndt Claudia¹,Bergmann Ralf¹,Loff Simon²³,Cartellieri Marc¹⁴,Bachmann Dominik²,Aliperta Roberta¹,Hetzenecker Mirjam²,Ludwig Florian²,Albert Susann²,Ziller-Walter Pauline²,Kegler Alexandra¹,Koristka Stefanie¹,Gärtner Sebastian¹,Schmitz Marc⁵⁶⁷,Ehninger Armin³,Ehninger Gerhard²⁸⁶⁷,Pietzsch Jens¹⁹,Steinbach Jörg¹⁶⁷⁹,Bachmann Michael¹²⁸⁶⁷

Affiliation:

1. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany

2. UniversityCancerCenter (UCC) ‘Carl Gustav Carus’ TU Dresden, Tumor Immunology, Dresden, Germany

3. GEMoaB Monoclonals GmbH, Dresden, Germany

4. Cellex Patient Treatment GmbH, Dresden, Germany

5. Institute of Immunology, ‘Carl Gustav Carus’, TU Dresden, Dresden, Germany

6. German Cancer Consortium (DKTK), partner site Dresden; and German Cancer Research Center (DKFZ), Heidelberg, Germany

7. National Center for Tumor Diseases (NCT), Dresden, ‘Carl Gustav Carus’ TU Dresden, Dresden, Germany

8. Medical Clinic and Policlinic I, University Hospital ‘Carl Gustav Carus’, TU Dresden, Dresden, Germany

9. Department of Chemistry and Food Chemistry, School of Science, TU Dresden, Dresden, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

2. 3D Microphysiological Tumor Model for Dual-Targeting CAR T Cell Immunotherapy;2024-08-16

3. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies;Frontiers in Immunology;2024-06-03

4. ⁶⁴Cu tumor labeling with hexadentate picolinic acid‐based bispidine immunoconjugates;Chemistry – A European Journal;2024-04-25

5. Significance of PSCA as a novel prognostic marker and therapeutic target for cancer;Cancer Cell International;2024-04-16